Efficacy of Heptral® in the treatment of hepatic toxicity induced by cytostatic chemotherapy
https://doi.org/10.17650/1994-4098-2010-0-2-47-52
Abstract
The efficacy of Heptral® (ademethionine) was evaluated in the treatment of chemotherapy-induced hepatotoxicity in 19 patients with various malignancies. Four-week administration of oral Heptral® 400 mg twice daily was shown to reduce the level of transaminases to normal values in 10 of 12 patients with grade 1 toxicity. Longer (2-to-4 month) use of Heptral® was required to normalize the level of transminases in grade 2 hepatotoxicity. The chemotherapy regimen was not changed during the use of this drug.
About the Authors
A. V. Snegovoy
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. V. Manzyuk
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. King P.D., Perry M.C. Hepatoioxiciry of chemotherapy. The Oncologist 2001;6:162–76.
2. DeLeve L.D., Kaplovitz N. Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:787–810.
3. Dansette P.M., Bonierbale E., Minoletti С. et al. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23: 443–51.
4. Kaplowitz N., Aw T.Y., Simon F.R., Stolz A. Drug-induced hepatotoxicity. Ann Intern Med 1986; 104: 826–39.
5. Ishak K.G., Zimmerman H.J. Morphologic spectrums of drug-induced liver disease. Gastroenterol Clin North Am 1995;24: 759–86.
6. Larrey D. Drug-induced liver diseases. J Hepatol 2000;32: 77–88.
7. Zorti D. et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. British Journal of Surgery 2007; 94: 274–86.
8. Paul D.King et al. Hepatotoxicity of chemotherapy. The Oncologist 2001;6:162–76.
9. O' Grady J.G. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997;26: 41–6.
10. Strieker B.H. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier, 1992.
11. Pessayre D., Larrey D., Biour M. Drug-induced liver injury. In: Bircher J., Benhamou J.P., Mcintire N., Rizzetto M., Rodes J., editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol 2, 1999, Oxford University Press, p. 1261–315.
12. Hirata F., Viveros O.H., Diliberto E.J.Jr., Axelrod J. Identification and properties of two methyltransferases in conversion of phosphatidylethanolamine to phosphatidylcholine. Proc Natl Acad Sci USA 1978;75: 1718–21.
13. Kretzschmar M., Klinger W. The hepatic glutathione system influences of xenobiotics. Exp Pathol 1990;38:145–64.
14. Cabrero C., Duce A.M., Ortiz P. et al. Specific loss of the high-molecular- weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis. Hepatology 1988; 8:1530–4.
15. Cantoni G.L. The nature of the active methyl donor formed enzymically from L-methionine and adenosine triphosphate. J Am Chem Soc 1952;74: 2942–3.
16. Dunne J.B., Davenport M., Williams R., Tredger J.M. Evidence that S-adenosylmethionine and
17. N-acetylcysteine reduce injury from sequential cold and warm ischaemia in the isolated perfused rat liver. Transplantation 1994; 57: 1161–8.
18. Mato J.M., Camara J., Fernandez de Paz J. et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081–9.
19. Giudici G.A., Le Grazie С., Di Padova C. The use of ademethionine (SAMe) in the treatmen of cholestatic
20. liver disorders: meta-analvsis of clinical trials. In: Мato JM, Lieber C, Kaplowitz N, Caballero A, editors. Methionine Metabolism: Molecular Mechanism and Clinical Implications. Madrid: CSIC Press, 1992; p. 67–9.
21. Feliu J., Mel J.R.. Camps C. et al. Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. An active and low toxicity regimen. Eur J Cancer 2002;З8; 1204–11.
22. Cascinu S., Graziano F., Ferrau F. et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002;13: 716–20.
Review
For citations:
Snegovoy A.V., Manzyuk L.V. Efficacy of Heptral® in the treatment of hepatic toxicity induced by cytostatic chemotherapy. Tumors of female reproductive system. 2010;(2):47-52. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-2-47-52
Views:
1770
Email this article 